Depemokimab for Asthma
Trial Summary
What is the purpose of this trial?
Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably. The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.
Research Team
GSK Clinical Trials
Principal Investigator
GlaxoSmithKline
Eligibility Criteria
This trial is for adults with asthma diagnosed at least 2 years ago, showing signs of type 2 inflammation (eosinophil count >=300 cells/mcL and FeNO >=25 ppb). They must have had at least two severe episodes in the past year despite using medium to high dose inhalers. Women must not be pregnant or breastfeeding and use effective contraception. Participants need uncontrolled asthma indicated by an ACQ-5 score >1.5.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive depemokimab to assess its effect on lung structure and function
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Depemokimab
Find a Clinic Near You
Who Is Running the Clinical Trial?
GlaxoSmithKline
Lead Sponsor
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School